Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide

Research output: Contribution to journalArticlepeer-review

Abstract

Several studies have reported an association between levels of circulating blood cells, in particular the neutrophil to lymphocyte ratio (absolute neutrophil count (ANC)/absolute lymphocyte count (ALC)) and outcomes in patients with cancer. In the current study, the association between lymphocyte, neutrophil, monocyte, and platelet counts and survival was examined in a prospective trial of preoperative pegylated-liposomal doxorubicin and ifosfamide for high-grade soft-tissue sarcomas. A statistically significant association between overall survival, but not progression free-survival, was observed with the ANC/ALC ratio at a cutoff value of ≥2 and a statistically significant trend using a cutoff of ≥5. Our results suggest that a balance between the lymphocyte count and the number of circulating myeloid cells that can suppress lymphocyte function may be predictive of survival in patients with soft-tissue sarcomas. Future research should therefore examine the role of lymphocyte-myeloid cell balance in sarcoma biology.

Original languageEnglish (US)
Article number3419
JournalCancers
Volume14
Issue number14
DOIs
StatePublished - Jul 2022

Bibliographical note

Funding Information:
We would like to thank the Kevin Franklin, James Dinnerstein, and James Swenson families, and the Karen Wyckoff Rein in Sarcoma Foundation for research support. Research reported in this publication was supported by NIH grant P30CA077598 utilizing the Biostatistics and Bioinformatics Core shared resource of the Masonic Cancer Center, University of Minnesota and by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1-TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2022 by the authors.

Keywords

  • anti-emetic
  • dexamethasone
  • doxorubicin
  • lymphocyte
  • monocyte
  • neutrophil
  • pegylated-liposomal doxorubicin
  • platelet
  • ratio
  • sarcoma

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide'. Together they form a unique fingerprint.

Cite this